Section Arrow
ONCY.NASDAQ
- Oncolytics Biotech
(Financial Status)
Quotes are at least 15-min delayed:2025/06/28 13:23 EDT
Last
 0.7506
+0.0306 (+4.25%)
Day High 
0.8 
Prev. Close
0.72 
1-M High
0.78 
Volume 
1.60M 
Bid
0.74
Ask
0.76
Day Low
0.7422 
Open
0.8 
1-M Low
0.3258 
Market Cap 
63.95M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 0.66 
20-SMA 0.53 
50-SMA 0.52 
52-W High 1.53 
52-W Low 0.3258 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.40/-0.40
Enterprise Value
64.74M
Balance Sheet
Book Value Per Share
0.05
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NCNANuCana plc0.0859+0.0033+4.00%-- 
INMBINmune Bio5.33-0.95-15.13%-- 
VORVor Biopharma1.06+0.17+19.10%-- 
OCGNOcugen0.9841-0.0459-4.46%-- 
RXRXRecursion Pharmaceuticals5.03-0.37-6.85%-- 
Quotes are at least 15-min delayed:2025/06/28 13:23 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.